Tag: market abuse
First published by Author on October 23, 2019 in the following categories: Advertising Consumer Law and tagged with advertising | cma | comparison sites | competition law | investigations | market abuse
The CMA (Competition and Markets Authority) is targeting fake and misleading online reviews because of the unfair impact it can have on competition within markets.
Nowadays, where most things can be bought and sold online, so can testimonials for products and services, and it’s this practice that the CMA’s aiming to stop. With how much influence the statements of other customers can have when it’s never been easier to shop around quickly, it seems that some companies are prepared to try and influence consumer choice with the power of fake reviews.
At the same time, it can be just as easy for someone to pay for bad reviews to hit one of their competitors as well.
Here’s the latest in the hydrocortisone tablets competition investigation that’s being conducted by the Competition and Markets Authority (CMA).
The history of this key study goes way back to October 2017 when the CMA started looking into alleged anti-competitive agreements and alleged abusive conduct. Exactly two years on, a great deal has happened as the CMA looks to ensure that the NHS and patients alike are not being ripped off by vastly wealthy pharmaceutical companies.
As we often say when the investigation involves the healthcare industry, this is a serious and important matter.
First published by Author on August 12, 2019 in the following categories: Market Sharing Price Fixing Price Hikes Pricing and tagged with cma | competition law | investigations | market abuse | marktet sharing | Pharmaceuticals | price fixing | pricing
In the latest investigation into suspected anti-competitive agreements for pharmaceutical drugs, a statement of objections has been issued by the CMA (Competition and Markets Authority).
The statement was issued last month and relates to a number of pharmaceutical companies who stand accused of participating in anti-competitive behaviour. Whether it’s a case of formal agreements in place, or concerted practices, the issue surrounds the supply of 50mg and 100mg nitrofurantoin capsules in the UK.
This investigation by the CMA into the practices of pharmaceutical firms is one of many that have been ongoing for a number of years. They’re one of the most important areas the CMA needs to safeguard.
First published by Author on May 30, 2019 in the following categories: Cartels Industry Market Sharing Price Fixing Price Hikes Pricing and tagged with cartels | cma | competition law | market abuse | marktet sharing | Pharmaceuticals | price fixing | pricing
There has been a provisional finding in the pharmaceuticals competition investigation by the Competition and Markets Authority (CMA) who have been looking into companies for quite some time.
It has been alleged that anti-competitive agreements are in place between four firms in the sector, and the calculated costs to the NHS is terrifying. If the provisional finding is formalised, huge fines could be issued to the alleged offenders involved in the investigation.
The costs of anti-competitive arrangements in the pharmaceutical industry often fall on the NHS, and therefore on the taxpayer, which is why these kinds of investigations are incredibly important.
First published by Author on April 04, 2019 in the following categories: Bid-Rigging Cartels Market Sharing Price Fixing Price Hikes Pricing and tagged with cartels | cma | cover bidding | cover pricing | market abuse | marktet sharing | price fixing | pricing
A huge £7m in total fines has been issued after five companies have admitted to breaches in the office fit-out competition case.
The Competition and Markets Authority (CMA) has been investigating the design, construction and fit-out services market since 2017. In July 2018, they decided to continue their probes, and in March this year, fines have been issued and agreed.
The five companies that have admitted to breaches and will be fined are Coriolis, Fourfront, Loop, Oakley and ThirdWay.
First published by Author on March 28, 2019 in the following categories: Latest Market Sharing Price Fixing Price Hikes Pricing and tagged with cma | investigations | market abuse | marktet sharing | overpriced medication | Pharmaceuticals | price fixing | pricing
There’s been a provisional finding by the Competition and Markets Authority (CMA) in the important hydrocortisone competition case, with a Statement of Objections issued.
In the coming weeks, the CMA expect written and oral representations to be made following the Statement of Objections that’s been issued.
The provisional findings of the CMA are incredibly worrying. It all comes down whether the two companies at the heart of the investigation colluded in order to charge higher prices and make bigger profits; all at the expense of our NHS, and our hard-earned tax money.
First published by Author on February 28, 2019 in the following categories: Investigations Price Hikes Pricing and tagged with cma | competition law | investigations | market abuse | price fixing | pricing
A brief update has been issued in the hypothyroidism tablets competition case surrounding alleged overcharging of liothyronine medication.
The liothyronine tablets are used to treat people lacking in thyroid hormones, which can lead to tiredness, slow metabolism, depression and other ailments. The CMA (Competition and Markets Authority) spent a great deal of time in 2017 gathering evidence for the case. In November 2017, a statement of objections was formally issued.
Last month, an updated statement of objections was issued by the CMA in this incredibly important investigation.
There’s been a huge development in the regulator’s funeral costs investigation that we’ve been tracking for a long time now.
The Regulators, the CMA (Competition and Markets Authority), are set to move from a market study to a referral for a market investigation. Their interim report states that there are “reasonable grounds for suspecting that a feature or combination of features of a market or markets in the UK prevents, restricts or distorts competition”.
The CMA now want to look into any adverse impact on the consumer. For a huge and sensitive market that’s worth something like £2bn a year, this is big news.
The regulatory investigation into online gambling competition led to undertaking being signed by key players in the market.
Undertakings are always a positive step in ensuring there’s fair competition in the market. The regulator, the Competition and Markets Authority (CMA), declared enforcement action earlier this year. Now, two big companies in the market have agreed to formal undertakings to improve their practises.
This should ensure that online gambling competition is healthy and consistent. This approach should always benefit the consumer.
There’s been an update in an ongoing most favoured nation clause competition law investigation being conducted by the CMA.
The CMA (Competition and Markets Authority) has an open investigation looking into whether there’s been a breach of competition law. This case surrounds the use of a ‘most favoured nation clause’ used by a price comparison website in the home insurance market.
The companies being investigated for alleged breaches of competition law include BGL (Holdings) Limited; BGL Group Limited; BISL Limited (BISL); and Compare The Market Limited.